Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The endometriosis market size across the 7MM was valued at $1.05 billion in 2020 and is expected to achieve a CAGR of more than 9% during 2020-2030. Women with endometriosis develop tissue that looks and acts like endometrial tissue outside of the uterus, usually on other reproductive organs inside the pelvis or in the abdominal cavity.

Risk factors for endometriosis include a family history of endometriosis, early age of menarche, short menstrual cycles, long duration of menstrual flow, heavy bleeding during menses, delayed childbearing, and defects in the uterus or fallopian tubes. Endometriosis typically develops on pelvic structures including the rectovaginal septum, bladder, ovaries, and fallopian tubes. However, it may also be found in more distant regions including the kidneys, bowels, intestines, lungs, and sometimes in the brain.

The endometriosis market research report provides an overview of endometriosis, including epidemiology, disease etiology, and management.

Endometriosis Market Outlook

Endometriosis Market OutlookTo gain more information about the endometriosis market forecast, download a free report sample

Endometriosis Market Drivers

Some of the major drivers of growth in the endometriosis market across the 7MM over the forecast period include improvements in noninvasive diagnostic methods, such as the utilization of biomarkers, the launch of Myovant’s Ryeqo (relugolix/estradiol/norethisterone acetate), and global launch of quinagolide, an endometriosis therapy that, unlike marketed therapies, does not interfere with ovulation.

Endometriosis Market Segmentation by Class of Drugs

The key classes of drugs in the US endometriosis market are GnRH agonists, Progestins, Estrogen antagonists, off-label, GnRH antagonists, and Dopamine D2 receptor antagonist. GnRH agonists accounted for the largest patient share in the US endometriosis market. The growth in US sales will mainly be driven by the uptake of the relugolix combination tablet, Myfembree, and Yselty (linzagolix), which will in turn stimulate sales of AbbVie’s Orilissa as GnRH antagonists populate the endometriosis market.

Endometriosis Market Analysis, by Class of Drugs in the US

Endometriosis Market Analysis, by Class of Drugs in the US

For more endometriosis classes of drugs insights, download a free report sample

Endometriosis Market - Competitive Landscape

Some of the leading players in the endometriosis market are AbbVie, Ipsen, Neurocrine Biosciences, DebioPharm Group, Ferring Pharmaceuticals, AstraZeneca, Mitsubishi Tanabe, Pfizer, Kissei Pharmaceuticals, Bayer, Gedeon Richter, and Evotec.

Endometriosis Market Report Overview

Market Size (2020) $1.05 billion
CAGR (2020 – 2030) >9%
Key Class of Drugs GnRH Agonists, Progestins, Estrogen Antagonists, Off-Label, GnRH Antagonists, and Dopamine D2 Receptor Antagonist
Leading Players AbbVie, Ipsen, Neurocrine Biosciences, DebioPharm Group, Ferring Pharmaceuticals, AstraZeneca, Mitsubishi Tanabe, Pfizer, Kissei Pharmaceuticals, Bayer, Gedeon Richter, and Evotec

Scope

This report provides:

  • Topline endometriosis drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), the annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global endometriosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global endometriosis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global endometriosis therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AbbVie
Ipsen
Neurocrine Biosciences
DebioPharm Group
Ferring Pharmaceuticals
AstraZeneca
Mitsubishi Tanabe
Pfizer
Kissei Pharmaceuticals
Bayer
Gedeon Richter
Evotec
Myovant Sciences
ObsEva
Astellas
Takeda
Nippon Shinyaku
Teva

Table of Contents

| Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Endometriosis: Executive Summary – Updated Dec 2022, Based on Events up to Nov 17, 2022

1.1 The Endometriosis Market Will Exhibit Considerable Growth Between 2020 and 2030

1.2 Current Therapies Leave Significant Unmet Needs in the Endometriosis Market

1.3 There Is a High Unmet Need for Earlier Endometriosis Diagnosis

1.4 Pipeline Therapies Present Promise in Closing Treatment Gaps

1.5 What Do Physicians Think?

2 Introduction – Updated Dec 2022, Based on Events up to Nov 17, 2022

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.4.3 Diagnosed Prevalent Cases of Endometriosis

4.4.4 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status

4.4.5 Diagnosed Prevalent Cases of Endometriosis by ASRM Stage

4.4.6 Diagnosed Prevalent Cases of Endometriosis by Phenotype

4.4.7 Germany and the UK

4.4.8 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy

4.4.9 Diagnosed Prevalent Cases of Endometriosis with Comorbidities

4.5 Epidemiological Forecast for Endometriosis (2020–2030)

4.5.1 Diagnosed Prevalent Cases of Endometriosis

4.5.2 Age-Specific Diagnosed Prevalent Cases of Endometriosis

4.5.3 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy

4.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage

4.5.5 Diagnosed Prevalent Cases of Endometriosis by Phenotype

4.5.6 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy

4.5.7 Diagnosed Prevalent Cases of Endometriosis with Comorbidities

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 Key Opinion Leader Insights on Disease Management

6 Competitive Assessment – Updated Dec 2022, Based on Events up to Nov 17, 2022

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated Dec 2022, Based on Events up to Nov 17, 2022

7.1 Overview

7.2 Noninvasive Diagnostics

7.3 Disease Awareness and Education of Medical Professionals

7.4 More Effective Drugs with Long-Term Safety and Tolerability

7.5 Non-Hormonal Therapies

7.6 Better Understanding of the Disease Etiology and Pathophysiology

8 R&D Strategies – Updated Dec 2022, Based on Events up to Nov 17, 2022

8.1 Overview

8.1.1 Reformulations and Label Expansion

8.1.2 The Race for the Development of GnRH Antagonists

8.1.3 Development of Novel Non-Hormonal Therapies

8.2 Clinical Trial Design

8.2.1 Pain Scales

8.2.2 Quality of Life Assessment as an Efficacy Tool

9 Pipeline Assessment – Updated Dec 2022, Based on Events up to Nov 17, 2022

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis – Updated Dec 2022, Based on Events up to Nov 17, 2022

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players – Updated Dec 2022, Based on Events up to Nov 17, 2022

11.1 Overview

11.1.1 AbbVie

11.1.1 Bayer

11.1.2 Evotec

11.1.3 Kissei

11.1.2 Myovant Sciences

11.1.4 Pfizer

11.1.5 Additional Companies

11.2 Deal-Making Trends

12 Market Outlook – Updated Dec 2022, Based on Events up to Nov 17, 2022

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – Key Opinion Leaders Interviewed for This Report

13.4.1 Key Opinion Leaders

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Epidemiology Reviewers

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Endometriosis: Key Metrics in the 7MM

Table 2: Role of the Different Theories in the Pathogenesis of Endometriosis

Table 3: Classifications of Endometriosis

Table 4: Risk Factors and Comorbidities for Endometriosis

Table 5: The Most Commonly Used Guidelines by Country

Table 6: AbbVie Portfolio Assessment, 2022

Table 7: Bayer Portfolio Assessment, 2022

Table 8: Evotec Portfolio Assessment, 2022

Table 9: Kissei Portfolio Assessment, 2022

Table 10: Myovant’s Portfolio Assessment, 2022

Table 11: Pfizer Portfolio Assessment, 2022

Table 12: Additional Companies Assessment, 2022

Table 13: Endometriosis Market – Global Drivers and Barriers, 2020–2030

Table 14: Key Events Impacting Sales for Endometriosis in the US, 2020–2030

Table 15: Endometriosis Market – Drivers and Barriers in the US, 2020–2030

Table 16: Key Events Impacting Sales for Endometriosis in the 5EU, 2020–2030

Table 17: Endometriosis Market – Drivers and Barriers in the 5EU, 2020–2030

Table 18: Key Events Impacting Sales for Endometriosis in Japan, 2020-2030

Table 19: Endometriosis Market – Drivers and Barriers in Japan, 2020–2030

Table 20: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Endometriosis in 2020 and 2030

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standards of Care (SOC): GnRH Agonists, Progestins, and Oral Contraceptives

Figure 3: Roles of estrogen receptor α and estrogen receptor β in normal endometrium and endometrial lesions

Figure 4: Endometrial lesions of varying depth

Figure 5: Sources of Estradiol in Endometriosis Tissue and Targets of the Current Medical Therapy

Figure 6: 7MM, Diagnosed Prevalence of Endometriosis, Women, %, Ages 12–54 Years, 2020

Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of Endometriosis

Figure 8: 7MM, Sources Used to Forecast the Laparoscopy Confirmation Status for the Diagnosed Prevalent Cases of Endometriosis

Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis by ASRM Stage

Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis by Phenotype

Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy

Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis with Comorbidities

Figure 13: 7MM, Diagnosed Prevalent Cases of Endometriosis, N, Women, Ages 12–54 Years, 2020

Figure 14: 7MM, Diagnosed Prevalent Cases of Endometriosis by Age, N, Women, 2020

Figure 15: 7MM, Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status, N, Women, Ages 12–54 Years, 2020

Figure 16: 7MM, Diagnosed Prevalent Cases of Endometriosis by Stage, N, Women, Ages 12–54 Years, 2020

Figure 17: 7MM, Diagnosed Prevalent Cases of Endometriosis by Phenotype, N, Women, Ages 12–54 Years, 2020

Figure 18: 7MM, Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy, N, Women, Ages 12–54 Years, 2020

Figure 19: 7MM, Diagnosed Prevalent Cases of Endometriosis with Comorbidity, N, Women, Ages 12–54 Years, 2020

Figure 20: Sample Endometriosis Treatment Algorithm

Figure 21: Unmet Needs and Opportunities in Endometriosis

Figure 22: Overview of the Development Pipeline in Endometriosis

Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Endometriosis in the 7MM During the Forecast Period

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standards of Care (SOC), GnRH Agonists, Progestins, and Oral Contraceptivesr

Figure 25: Analysis of the Company Portfolio Gap in Endometriosis During the Forecast Period

Figure 26: Deal-Making Trends, 2017–2022

Figure 27: Global (7MM) Sales Forecast by Country for Endometriosis in 2020 and 2030

Figure 28: Sales Forecast by Class for Endometriosis in the US in 2020 and 2030

Figure 29: Sales Forecast by Class for Endometriosis in the 5EU in 2020 and 2030

Figure 30: Sales Forecast by Class for Endometriosis in Japan in 2020 and 2030

Frequently asked questions

Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 in real time.

  • Access a live Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.